Pfizer (NYSE:PFE) Stock Price Up 1.7% After Dividend Announcement

Posted by Geri Gentry on Oct 7th, 2026

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) traded up 1.7% during mid-day trading on Wednesday following a dividend announcement from the company. The company traded as high as $28.17 and last traded at $27.9640. Approximately 30,161,760 shares were traded during trading, a decline of 25% from the average daily volume of 40,481,164 shares. The stock had previously closed at $27.50.

The newly announced dividend which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is 226.32%.

Analyst Ratings Changes

A number of brokerages have weighed in on PFE. BMO Capital Markets decreased their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. HSBC boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. lowered their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Five equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.56.

Get Our Latest Report on PFE

Pfizer Stock Up 1.7%

The company’s 50 day moving average price is $27.50 and its two-hundred day moving average price is $26.48. The firm has a market cap of $159.39 billion, a PE ratio of 36.80, a PEG ratio of 1.84 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the business posted $0.78 EPS. Pfizer’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: The FDA approved Pfizer’s TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a first-line maintenance treatment for advanced HER2-positive breast cancer. The expanded indication could increase the drug’s addressable market and support Pfizer’s oncology portfolio. Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease
Positive Sentiment: Phase 3 results for oral LITFULO showed meaningful facial and total-body repigmentation in patients with nonsegmental vitiligo, along with favorable tolerability. Pfizer plans regulatory submissions, potentially broadening the drug’s immunology opportunity. Pfizer Posted Positive Phase 3 Vitiligo Results for LITFULO
Positive Sentiment: Pfizer declared a quarterly dividend of $0.43 per share, equal to $1.72 annually and a yield of approximately 6.3% based on the cited share price. The payout supports the stock’s appeal to income-focused investors. Pfizer Declares Fourth-Quarter 2026 Dividend
Neutral Sentiment: Pfizer raised its 2026 revenue guidance while maintaining earnings guidance and announcing additional cost reductions. However, the second-quarter results included a $0.04 per-share loss, highlighting pressure on profitability despite the improved revenue outlook. Pfizer Trades Below Its Own Average Multiple
Negative Sentiment: Pfizer will reportedly eliminate roughly 330 jobs at its Sicily plant in Italy. The cuts may reduce costs, but they also underscore ongoing restructuring and operational pressure. Pfizer to Cut Around 330 Jobs in Italy
Negative Sentiment: Vaxcyte’s positive Phase 3 results for VAX-31 intensified concerns about competition to Pfizer’s major Prevnar franchise, which generated approximately $6.5 billion in revenue. A successful rival vaccine could pressure future sales and pricing. Pfizer’s Prevnar Franchise Faces a New Challenger
Negative Sentiment: Recent coverage highlights concern that Pfizer’s dividend payout substantially exceeds reported earnings, raising questions about its long-term sustainability if profitability does not improve. Is Pfizer a Good or Bad Investment at Today’s Price?

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PFE. BlackRock Inc. raised its stake in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. State Street Corp increased its stake in shares of Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Pfizer by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock worth $1,393,739,000 after purchasing an additional 3,999,646 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Pfizer during the 2nd quarter valued at $1,049,602,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Pfizer by 0.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock valued at $1,022,606,000 after buying an additional 293,029 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

About Pfizer

(Get Free Report)

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.